Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.93 |
| ▸ | PKM | P14618 | 1/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.93 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.93 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.93 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.89 |
| ▸ | MAP3K5 | Q99683 | 12/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26458799 | 0.96 | MEN1 (1.00) | MEN1PKMKMT2AMCL1TDP1 | |
| Claficapavir SCHEMBL12697026 | 0.94 | HIF1AN (1.00) | MEN1PKMKMT2AMCL1TDP1 | |
| Claficapavir SCHEMBL6789043 | 0.94 | HIF1AN (1.00) | MEN1PKMKMT2AMCL1TDP1 | |
| Claficapavir SCHEMBL13326245 | 0.94 | HIF1AN (1.00) | MEN1PKMKMT2AMCL1TDP1 | |
| SCHEMBL15827151 | 0.90 | MAP3K5 (0.79) | MEN1PKMKMT2AMCL1TDP1 | |
| SCHEMBL14860012 | 0.90 | MAP3K5 (0.79) | MEN1PKMKMT2AMCL1TDP1 | |
| SCHEMBL14860010 | 0.90 | MAP3K5 (0.79) | MEN1PKMKMT2AMCL1TDP1 | |
| SCHEMBL8290399 | 0.89 | MAP3K5 (0.79) | MEN1PKMKMT2AMCL1TDP1 | |
| SCHEMBL13056328 | 0.88 | HIF1AN (0.81) | MEN1PKMKMT2AMCL1TDP1 | |
| SCHEMBL3892576 | 0.88 | HIF1AN (0.81) | MEN1PKMKMT2AMCL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3243513-B1 | USE OF THE RNASE INHIBITOR RNPA-3000 FOR TREATING STAPHYLOCOCCUS INFECTIONS | UNIV ROCHESTER (US) | 2019-06-05 | — | — | EP | disclosed |